États-Unis · Plateformes & données · MarketBeat

Tonix Pharmaceuticals’ TONMYA Sales Jump 37% as Insurance Coverage Expands

Publié par MarketBeat · États-Unis il y a 21 min

Image from MarketBeat Media, LLC. · MarketBeat

Résumé détaillé

Tonix Pharmaceuticals (NASDAQ:TNXP) said sales of its fibromyalgia treatment TONMYA rose 37% in the third quarter, as the company expanded insurance access and increased its sales force. Chief Executive Seth Lederman told biopharma analyst Vamil Divan at the Guggenheim Healthcare Innovation Confere

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Tonix Pharmaceuticals’ TONMYA Sales Jump 37% as Insurance Coverage Expands

Résumé détaillé

À lire aussi

D-Wave Quantum: 3 Key Takeaways for Long-Term Investors

Grocery Outlet outlines Q4 comp of 1.5% to 2.5% as opportunistic mix drives return to positive comps

Alibaba announces plans to list T-Head, its Nvidia chip rival

‘The thought of living to 100 terrifies me’: Is Social Security a giant Ponzi scheme?

World leaders to address COP31 as Turkey pushes for new climate deal

ONDS Stock Rises Overnight: Ondas Scores New ‘Digital Bat’ Drones Order Ahead Of Earnings

Tonix Pharmaceuticals’ TONMYA Sales Jump 37% as Insurance Coverage Expands

Résumé détaillé

Partager

À lire aussi

D-Wave Quantum: 3 Key Takeaways for Long-Term Investors

Grocery Outlet outlines Q4 comp of 1.5% to 2.5% as opportunistic mix drives return to positive comps

Alibaba announces plans to list T-Head, its Nvidia chip rival

‘The thought of living to 100 terrifies me’: Is Social Security a giant Ponzi scheme?

World leaders to address COP31 as Turkey pushes for new climate deal

ONDS Stock Rises Overnight: Ondas Scores New ‘Digital Bat’ Drones Order Ahead Of Earnings